Phase II

Trial Results Anticipated First Half 2019

iX Biopharma Ltd will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark.

Top-line Data Expected Early in the First Quarter of 2019

Galapagos NV reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).

Karolinska Development announces today top line results from a Phase 2b study with tafoxiparin in treatment of protracted labor. The results show that the study did not achieve its primary endpoint of reducing the time to vaginal delivery through treatment with tafoxiparin. Karolinska Development will revalue the portfolio company’s book value, which is expected to negatively impact the result by SEK 40 million for the fourth quarter of 2018.

Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.

VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.

Checkpoint inhibitors are only effective against inflamed tumors, called ‘hot’ tumors. Unfortunately, most tumors are ‘cold’ (not inflamed) and hide from the immune system by appearing to be too similar to normal cells.

InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).

Theranexus announces today that it has recruited the last patient in its Phase II trial, entitled “Tolerance and Efficacy of THN102 on Sleepiness in Narcoleptic Patients”.